For the year ending 2025-12-31, AVBP has $333,169K in assets. $25,945K in debts. $45,540K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 45,540 | |||
| Short-term investments | 267,281 | |||
| Prepaid expenses and other current assets | 20,076 | |||
| Total current assets | 332,897 | |||
| Right of use assets - operating leases | 13 | |||
| Deferred offering costs | 69 | |||
| Other assets | 190 | |||
| Total assets | 333,169 | |||
| Accounts payable | 5,934 | |||
| Accrued expenses | 19,997 | |||
| Operating lease liabilities | 14 | |||
| Total current liabilities | 25,945 | |||
| Total liabilities | 25,945 | |||
| Common stock 0.0001 par value, 200,000,000 shares authorized 42,452,251 and 33,706,765 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 4 | |||
| Additional paid-in capital | 711,847 | |||
| Accumulated deficit | -404,641 | |||
| Accumulated other comprehensive income (loss) | 14 | |||
| Total stockholders' equity | 307,224 | |||
| Total liabilities and stockholders' equity | 333,169 | |||
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)